Clinical Trials on Non Hodgkin's Lymphoma

Total 21564 results

TG Therapeutics, Inc.

Completed

Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

B-cell Lymphoma | Marginal Zone Lymphoma | Primary Central Nervous System Lymphoma | Waldenstrom's Macroglobulinemia | Non-Hodgkins Lymphoma | Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL)

United States
Western Regional Medical Center

Withdrawn

Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)

Lymphoma | Hodgkin's Lymphoma | Non-hodgkin's Lymphoma

United States
Shanghai Hengrui Pharmaceutical Co., Ltd.

Recruiting

A Trial of SHR-A1912 Combined With Other Therapies in B-cell Non-Hodgkin 's Lymphoma

B-cell Non-Hodgkin's Lymphoma

China
Shanghai Henlius Biotech

Completed

A Pharmacokinetic and Pharmacodynamic Study Comparing HLX01 And Rituximab in Patients With CD20-Positive, B-cell Lymphoma

B-cell Non Hodgkin's Lymphoma
Shanghai Henlius Biotech

Completed

Clinical Study to Compare the Efficacy and Safety of Rituximab Biosimilar HLX01 and Rituximab in Combination With CHOP, in Previously Untreated Subjects With CD20+ DLBCL

B-cell Non Hodgkin's Lymphoma

China
Institut Paoli-Calmettes

Completed

Unicentric Retrospective Analysis of a Cohort of 602 Young Adult and Adolescent Patients (AJA), Aged 15 to 30 Years, With Haematological Malignancies, and Managed Between 2000 and 2016 (HEMAJA)

Hodgkin Lymphoma | Acute Leukemia | Non-hodgkin Lymphoma | Malignant Haemopathies

France
National Cancer Institute (NCI)

Enrolling by invitation

Biology Studies of Hematologic Cancers

Acute Lymphoblastic Leukemia | Acute Myelogenous Leukemia | Non-Hodgkins Lymphoma | Myelodysplastic Syndrome (MDS) | Hodgkins Lymphoma

United States
Genzyme, a Sanofi Company

Completed

Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM).

Lymphoma | Multiple Myeloma | Non Hodgkin's Lymphoma | Hodgkin's Disease

Germany
Institut Bergonié
National Cancer Institute, France

Completed

Diffuse Large B Cell Non-Hodgkin's Lymphoma in the Vulnerable/Frail Elderly. A Multicentric Randomized Phase II Trial (FRAIL-06)

Lymphoma

France
Beth Israel Deaconess Medical Center

Completed

Y 90 Ibritumomab Tiuxetan &Rituximab Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Lymphoma

United States
M.D. Anderson Cancer Center
Genentech, Inc.

Completed

Avastin Plus Rituximab for Patients With B-Cell Non-Hodgkin's Lymphoma

Lymphoma

United States
Federal University of Minas Gerais

Completed

Evaluation of the Analgesy With Emla and/or Nitrous Oxide in Pediatric Patients for Lumbar Puncture

Leukemia | Non Hodgkin Lymphoma

Brazil
Azienda Ospedaliera San Giovanni Battista

Unknown

Thiotepa, Busulfan and Fludarabin for pt With Refractory/Early Relapsed Aggressive B-cell Non Hodgkin Lymphomas (TBF)

B-cell Lymphoma Refractory

Italy
National Cancer Institute (NCI)

Active, not recruiting

Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma

Recurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Refractory Mantle Cell Lymphoma

United States
He Huang
Gracell Biotechnology Ltd.

Not yet recruiting

Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin Lymphoma

Relapsed and Refractory | Lymphoid Hematological Malignancies

China
NCIC Clinical Trials Group
Eli Lilly and Company

Completed

Combination Chemotherapy in Hodgkin's Disease or Non-Hodgkin's Lymphoma Not Responding to Previous Treatment

Lymphoma

Canada
AHS Cancer Control Alberta
Alberta Cancer Foundation; Celgene Corporation

Completed

A Phase II Clinical Trial of Lenalidomide for T-cell Non-Hodgkin's Lymphoma

T-cell Lymphoma

Canada
University Hospital Freiburg
University Hospital Tuebingen

Unknown

Freiburg ZNS-NHL Study

Primary Non Hodgkin Lymphoma of the Central Nervous System

Germany
Yogen Saunthararajah

Completed

p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies

T-cell Lymphoma | Indolent B-cell Lymphoma | Aggressive B-cell Lymphoma | Non-Hodgkin's Lymphomas

United States
European Organisation for Research and Treatment...

Unknown

Combination Chemotherapy Plus Steroid Therapy in Treating Children With Acute Lymphoblastic Leukemia or Lymphoblastic Non-Hodgkin's Lymphoma

Lymphoma | Leukemia

France, Belgium, Portugal
University of Bologna

Unknown

Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults

Non-Hodgkin's Lymphoma | Acute Lymphoblastic Leukemia

Italy
Biocad

Completed

Safety and Efficacy Study of BCD-020 in Therapy of Indolent Non-Hodgkin's Lymphoma

Splenic Marginal Zone Lymphoma | Nodal Marginal Zone Lymphoma | Follicular Non-Hodgkin's Lymphoma

India, Russian Federation, Colombia, South Africa, Ukraine
Northwestern University
National Cancer Institute (NCI)

Not yet recruiting

Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

B-Cell Non-Hodgkin Lymphoma

United States
M.D. Anderson Cancer Center
Genentech, Inc.

Completed

Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger

Lymphoma

United States
University of California, San Francisco

Terminated

A Pilot Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide (RICE) Plus Bortezomib (Velcade) in a Dose-Escalating Fashion for Patients With Relapsed or Primary Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma Who Are Candidates for Autologous Stem Cell Transplant

Lymphoma, B-Cell

United States
Merck Sharp & Dohme LLC

Completed

Study of Vorinostat (MK-0683) With Follicular Lymphoma (FL), Other Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL), or Mantle Cell Lymphoma (MCL) Participants (MK-0683-103)

Lymphoma
Kite, A Gilead Company

Active, not recruiting

A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA-5)

Follicular Lymphoma | Marginal Zone Lymphoma | Indolent Non-Hodgkin Lymphoma

United States, France
Genzyme, a Sanofi Company

Completed

A Multi-centre, Open Label, Single-arm Study Intended to Further Investigate the Safety and Efficacy of Plerixafor as a Front-line Mobilisation Agent in Combination With G-CSF in Patients With Lymphoma or MM (Multiple Myeloma). (PREDICT)

Transplantation | Lymphoma (Non-Hodgkin's Lymphoma) | Hodgkin's Disease or Multiple Myeloma | Front Line Mobilization

Netherlands, France, Germany, Sweden, Spain, Italy, United Kingdom
Mirati Therapeutics Inc.

Terminated

MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin Lymphoma

Hodgkin Lymphoma | Non-Hodgkin Lymphoma (Follicular or Large Diffuse B-cell Lymphoma or Mantle Cell Lymphoma)

United States
The Lymphoma Academic Research Organisation

Active, not recruiting

Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma

Aggressive Non-Hodgkin Lymphoma

France, Belgium
International Extranodal Lymphoma Study Group (IELSG)

Completed

A Clinico-Pathological Study to Investigate the Possible Infective Causes of Non-Hodgkin Lymphoma of the Ocular Adnexae (IELSG27)

Non-Hodgkin Lymphoma

Spain, Italy, Switzerland, Chile
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Active, not recruiting

T-cells or EBV Specific CTLs, Advanced B-Cell NHL and CLL (ATECRAB)

Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma

United States
Incyte Corporation

Active, not recruiting

A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL) (topMIND)

Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma

United States, Spain, France, Italy, Belgium, Germany, Austria
Autolus Limited

Recruiting

A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia | Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

United Kingdom
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma

Refractory Hodgkin Lymphoma | Recurrent Adult Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Prolymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | T-Cell Chronic Lymphocytic Leukemia | Recurrent Childhood Non-Hodgkin... and other conditions

United States, Germany
University of Nebraska
Bristol-Myers Squibb

Recruiting

Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma

Follicular Lymphoma | Refractory Non-Hodgkin Lymphoma | High-grade B-cell Lymphoma | DLBCL - Diffuse Large B Cell Lymphoma | Relapsed Non-Hodgkin Lymphoma | Mediastinal Large B-cell Lymphoma | Indolent B-Cell Non-Hodgkin Lymphoma

United States
Kronos Bio

Recruiting

A Dose Escalation and Cohort Expansion Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors or Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma | Refractory Solid Tumors | Relapsed Solid Tumors

United States, Spain, United Kingdom
GPCR Therapeutics, Inc.

Completed

Safety and PK/PD of TG-0054 in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients

Multiple Myeloma | Hodgkin Disease | Non-Hodgkin Lymphoma

Taiwan
Fondazione Italiana Linfomi - ETS

Recruiting

Quality Of Life On Elderly Patients With Low Grade Non-Hodgkin Lymphoma

Low Grade Non-Hodgkin's Lymphoma, Adult

Italy
Dana-Farber Cancer Institute
Beth Israel Deaconess Medical Center; Brigham and Women's Hospital

Terminated

Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma

Burkitt Lymphoma | Non-Hodgkins Lymphoma | Atypical Burkitt Lymphoma

United States
Zhejiang University

Recruiting

A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Malignancies

Non-Hodgkin's Lymphoma | Acute Lymphoblastic Leukemia

China
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Completed

Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia and Diffuse Non-Hodgkin's Lymphoma

Lymphoma | Leukemia

United States, Egypt, India
Gilead Sciences

Terminated

Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Non-hodgkin's Lymphoma | Small Lymphocytic Lymphoma

United States
Akdeniz University

Not yet recruiting

The Effect of Decision Support System on Symptom Self-Management in Non-Hodgkin Lymphoma Patients (LympSCare)

Non-Hodgkin Lymphoma | Decision Support System
iOMEDICO AG
Amgen

Completed

Patient Preference for Pegfilgrastim (Neulasta®) Application Forms (CONVENIENCE)

Breast Cancer | Non Hodgkin Lymphoma

Germany
Genentech, Inc.

Completed

A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) (ROMULUS)

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma

United States, Canada, France, Italy, Germany, Netherlands
Norwegian University of Science and Technology
Oslo University Hospital; St. Olavs Hospital; Norwegian Cancer Society

Active, not recruiting

Goal Management Training for Adult Survivors of Childhood Leukemia and Non-Hodgkins Lymphoma With Neurocognitive Sequelae

Childhood Acute Lymphoblastic Leukemia | Childhood Acute Myeloid Leukemia | Childhood Non-Hodgkin Lymphoma

Norway
Ottawa Hospital Research Institute

Unknown

Does CMV Induced Changes in NK Lymphocyte Biology Influence the Effectiveness of Antibody Therapy Used to Treat B Cell Lymphoproliferative Diseases?

B Cell Non-Hodgkin's Lymphoma | B Cell Lymphocytic Leukemia
National Institute on Aging (NIA)
National Cancer Institute (NCI)

Completed

Bryostatin 1 and Rituximab in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Lymphoma | Leukemia

United States
Astex Pharmaceuticals, Inc.

Terminated

Safety of SGI-1776, A PIM Kinase Inhibitor in Refractory Prostate Cancer and Relapsed/Refractory Non Hodgkin's Lymphoma

Prostate Cancer | Non-Hodgkins Lymphoma

United Kingdom, United States

Clinical Trials on Non Hodgkin's Lymphoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kuwait

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations